CYTOF · Altamira Therapeutics Ltd. · Financials
Market Cap
$514,392
Shares
5.72M
Volume · Oct 20
1600
Avg daily vol (3M)
5272
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$8.2M
-23.6%
FY2020
Diluted EPS
-$2.99
+65.9%
FY2024
Operating Cash Flow
-$6.11M
+52.3%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| CHF | — | 255.59K | 305.62K | 63.88K | 174.48K |
| CHF | — | 33.97K | 1.44M | 2.24M | — |
| CHF | — | — | -1.14M | -2.18M | — |
| CHF | — | — | 2.38M | 1.5M | — |
| USD/shares | -$2.99 | -$8.77 | -$610.03 | — | — |
| USD/shares | -$2.99 | -$8.77 | -$610.03 | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current lease liabilities | 2025-06-30 | USD 145,852 | 6-K filed 2025-08-29 |
| Current portion of long-term borrowings | 2025-06-30 | USD 430,841 | 6-K filed 2025-08-29 |
| Noncurrent lease liabilities | 2025-06-30 | USD 198,762 | 6-K filed 2025-08-29 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.